Entasis Therapeutics Holdings Inc.

NasdaqGM:ETTX Rapporto sulle azioni

Cap. di mercato: US$104.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Entasis Therapeutics Holdings Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Manos Perros

Amministratore delegato

US$2.0m

Compenso totale

Percentuale dello stipendio del CEO27.0%
Mandato del CEO7.2yrs
Proprietà del CEO0.2%
Durata media del management3yrs
Durata media del Consiglio di amministrazione4.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Will Entasis Therapeutics Holdings (NASDAQ:ETTX) Spend Its Cash Wisely?

Dec 16
Will Entasis Therapeutics Holdings (NASDAQ:ETTX) Spend Its Cash Wisely?

Entasis Therapeutics: AstraZeneca Spin-Out Developing Targeted Antibacterial Products

Nov 17

Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?

Aug 19
Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?

Entasis Therapeutics shares rise after lining up ETX0462 poster presentation

Jun 18

What Kind Of Shareholders Own Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX)?

Feb 17
What Kind Of Shareholders Own Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX)?

Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?

Dec 01
Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Manos Perros rispetto agli utili di Entasis Therapeutics Holdings?
DataCompenso totaleStipendioGuadagni aziendali
Mar 31 2022n/an/a

-US$52m

Dec 31 2021US$2mUS$553k

-US$47m

Sep 30 2021n/an/a

-US$46m

Jun 30 2021n/an/a

-US$45m

Mar 31 2021n/an/a

-US$46m

Dec 31 2020US$1mUS$537k

-US$50m

Sep 30 2020n/an/a

-US$54m

Jun 30 2020n/an/a

-US$46m

Mar 31 2020n/an/a

-US$46m

Dec 31 2019US$1mUS$495k

-US$44m

Sep 30 2019n/an/a

-US$38m

Jun 30 2019n/an/a

-US$52m

Mar 31 2019n/an/a

-US$44m

Dec 31 2018US$2mUS$450k

-US$42m

Sep 30 2018n/an/a

-US$43m

Jun 30 2018n/an/a

-US$34m

Mar 31 2018n/an/a

-US$35m

Dec 31 2017US$1mUS$430k

-US$30m

Dec 31 2016US$761kUS$413k

-US$19m

Compensazione vs Mercato: La retribuzione totale di Manos ($USD 2.05M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 646.00K ).

Compensazione vs guadagni: La retribuzione di Manos è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

Manos Perros (54 yo)

7.2yrs

Mandato

US$2,047,687

Compensazione

Dr. Manoussos Perros, Ph D., also known as Manos, serves as the Chief Executive Officer, President & Director at Entasis Therapeutics Inc. Dr. Perros has been President, Chief Executive Officer and Directo...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Manoussos Perros
President7.2yrsUS$2.05m0.17%
$ 174.7k
Ruben Tommasi
Chief Scientific Officer7.2yrsUS$998.39k0.098%
$ 103.0k
David Altarac
Chief Medical Officer2.7yrsUS$1.09m0.052%
$ 54.7k
Kristie Wagner
Interim VP and Interim Principal Financial & Accounting Officerless than a yearNessun datoNessun dato
Elizabeth Keiley
General Counsel3.3yrsNessun dato0.35%
$ 367.0k
John Mueller
Chief Development Officer7.2yrsUS$754.14k0.35%
$ 365.9k
Matthew Ronsheim
Chief Pharmaceutical Sciences & Manufacturing Officer1.8yrsNessun dato0.35%
$ 367.0k
Anna Triola
Chief Commercial Officerless than a yearNessun dato0.26%
$ 273.7k

3.0yrs

Durata media

55.5yo

Età media

Gestione esperta: Il team dirigenziale di ETTX è considerato esperto (durata media dell'incarico 3 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Manoussos Perros
President7.2yrsUS$2.05m0.17%
$ 174.7k
David Hastings
Independent Director4.3yrsUS$153.23k0.046%
$ 48.2k
Louis Rice
Member of Scientific & Clinical Board1.9yrsNessun datoNessun dato
Heather Preston
Independent Director4.9yrsUS$49.00kNessun dato
Karen Bush
Member of Scientific & Clinical Boardno dataNessun datoNessun dato
Helen Boucher
Member of Scientific & Clinical Boardno dataNessun datoNessun dato
Howard Mayer
Independent Director2.9yrsUS$123.05k0.046%
$ 48.2k
Heather Berger
Independent Director4.9yrsUS$132.33k0.046%
$ 48.2k
Paul Ambrose
Member of Scientific & Clinical Boardno dataNessun datoNessun dato
David Meek
Independent Chairman of the Board3.1yrsUS$174.28k0.046%
$ 48.2k
Mark Noe
Member of Scientific & Clinical Boardno dataNessun datoNessun dato
Andrew Shorr
Member of Scientific & Clinical Boardno dataNessun datoNessun dato

4.3yrs

Durata media

57.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ETTX sono considerati esperti (durata media dell'incarico 4.3 anni).